Advancing Minimally Invasive Treatments for Osteoporotic Vertebral Fractures
Spine Chronicle Japan Co., Ltd. has successfully raised 135 million yen in a Series A funding round. The company, focused on developing minimally invasive spinal treatment devices for elderly patients with refractory osteoporotic vertebral fractures, secured the funding through a third-party allotment of new shares. The lead investors include Diamond Medino Capital Co., Ltd. and other prominent backers.
This investment will speed up the testing of innovative devices. They aim to get medical device approval and improve spinal treatment outcomes.
Focus on Cutting-Edge Technology for Spinal Care
Spine Chronicle Japan is prioritizing two products in its current development pipeline:
SCJ-001: A Modified Kyphoplasty Kit
SCJ-002: A Screw-Anchored Kyphoplasty Kit
These products aim to meet the demand for better treatments for spinal diseases, like osteoporotic fractures. These are common in Japan’s ageing population.
Traditional treatments, like vertebroplasty and spinal surgery, often face issues. These include implant loosening, cement instability, and new fractures. Spine Chronicle Japan’s innovations aim to overcome these limits. They use advanced materials for vertebral body formation and screw-based implants for stronger internal fixation. These technologies are expected to improve patient recovery times, quality of life, and overall treatment efficacy while minimizing surgical invasiveness.
Future Outlook
Spine Chronicle Japan plans to complete regulatory approval for SCJ-001 and SCJ-002 in Japan by fiscal year 2025. Simultaneously, clinical trials will be conducted for additional pipeline products, such as SCJ-003 and SCJ-004, which are designed to stabilize vertebral fractures and lumbar spinal stenosis without relying on conventional spinal fixation methods.
Investor Perspectives
Diamond Medino Capital Co., Ltd.
Director Tetsuya Ishimaru “Spine Chronicle Japan’s commitment to advancing spinal treatment is inspiring. By leveraging the expertise of CEO Yonezawa and our experience in the medical device approval process, we aim to bring these innovative solutions to the global market and drive significant growth for the company.”
Lifetime Ventures
Managing Partner Ryosuke Kimura “Having supported Spine Chronicle Japan since its pre-seed round, it’s rewarding to see their continued growth. We remain dedicated to delivering transformative solutions from Japan to address challenges in aging societies worldwide.”
Hokuriku Startup Community Fund
HED Corporation Representative Director Satoshi Takada “CEO Yonezawa’s dedication to advancing medical technology is commendable. With the addition of a strong partner like Diamond Medino Capital, Spine Chronicle Japan is poised for significant progress, and we are proud to support their journey.”
CEO’s Vision
Founder and CEO, Noritaka Yonezawa “As a spine surgeon, I’ve witnessed the challenges faced by elderly patients in spinal care. With our investors’ support, we can now speed up the development of life-changing medical devices. Together, we aim to bring these solutions to patients worldwide.”
